Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1479-1489

  Alexander Jr , H Richard ^a   Bartlett, David L ^a   Libutti, Steven K ^a   Fraker, Douglas L ^a   Moser, Tammy ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SERUM ALBUMIN I 131; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; AXILLARY VEIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXTRACORPOREAL CIRCULATION; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; INFERIOR CAVA VEIN; LAPAROTOMY; LIVER CANCER; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MALE; MORTALITY; PHASE 2 CLINICAL TRIAL; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL;

EID: 0345596439     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1479     Document Type: Article

References (65)

1. Daly JM, Kemeny NE: Metastatic cancer to the liver, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 2551-2570
2. Weiss L, Grundman E, Torhurst J, et al: Hemotagenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 150:195-203, 1986
3. Kath R, Hayungs J, Bornfeld N, et al: Prognosis and treatment of disseminated uveal melanoma. Cancer 72:2219-2223, 1993
4. Seregard S, Kock E: Prognostic indicators following enucleation for posterior uveal melanoma. Acta Opthalmol Scand 73:340-344, 1995
5. Rajpal S, Moore R, Karakousis CP: Survival in metastatic ocular melanoma. Cancer 52:334-336, 1983
6. Bedikian AY, Legha SS, Mavligit G, et al: Treatment of uveal melanoma metastatic to the liver. Cancer 76:1665-1670, 1995
7. Kemeny N, Seiter K, Conti JA, et al: Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer 73:1134-1142, 1994
8. Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685-693, 1987
9. Rougier P, LaPlanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 10:1112-1118, 1992
10. Carr BI, Flickinger JC, Lotze MT: Hepatobiliary cancers, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1087-1114
11. Pentecost MJ: Transcatheter treatment of hepatic metastases. Am J Roentgenol 160:1171-1175, 1993
12. Onik GM, Atkinson D, Zemel R, et al: Cryosurgery of liver cancer. Semin Surg Oncol 9:309-317, 1993
13. Ravikumar TS, Kane R, Cady B, et al: A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg 126:1520-1524, 1991
14. Murakami R, Yoshimatsu S, Yamashita Y, et al: Treatment of hepatocellular carcinoma: Value of percutaneous microwave coagulation. Am J Roentgenol 164:1159-1164, 1995
15. Lee MJ, Mueller PR, Dawson SL, et al: Percutaneous ethanol injection for the treatment of hepatic tumors: Indications, mechanism of action, technique, and efficacy. Am J Roentgenol 164:215-220, 1995
16. Alexander HR, Bartlett DL, Fraker DL, et al: Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. Principles and Practice of Oncology Updates 10:1-19, 1996
17. Ausman RK: Development of a technic for isolated perfusion of the liver. N Y State J Med 61:3393-3397, 1961
18. Aigner KR, Walther H, Tonn JC, et al: Die isolierte leberperfusion bei fortgeschrittenen metastasen kolorektaler karzinome. Onkologie 7:13-21, 1984
19. Aigner K, Walther H, Tonn J, et al: First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary. Recent Results Cancer Res 86:99-102, 1983
20. Schwemmle K, Link KH, Rieck B: Rationale and indications for perfusion in liver tumors: Current data. World J Surg 11:534-540, 1987
21. Marinelli A, de Brauw LM, Beerman H, et al: Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 26:341-350, 1996
22. van Zuidewign DBW, de Brauw LM, Marinelli A, et al: Isolated liver perfusion with mitomycin-C or melphalan in patients with hepatic metastases. Soc Surg Oncol 46:198, 1993
23. Hafström LR, Holmberg SB, Naredi PLJ, et al: Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 3:103-108, 1994
24. Skibba JL, Quebbeman EJ, Komorowski RA, et al: Clinical results of hyperthermic liver perfusion for cancer in the liver, in Aigner KR, Patt YZ, Link KH, Kreidler J (eds): Regional Cancer Treatment (ed 29). Basel, Switzerland, Karger, 1988, pp 222-228
25. Skibba JL, Quebbeman EJ: Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg 121:1266-1271, 1986
26. Fraker DL, Alexander HR, Thom AK: Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 44:45-50, 1994
27. Fraker DL: Use of high-dose tumor necrosis factor in isolation perfusion of the limbs and liver. Reg Cancer Treat 8:37-41, 1995
28. Lienard D, Ewalenko P, Delmotti JJ, et al: High-dose recombinant tumor necrosis factor-alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60, 1992
29. Fraker DL, Alexander HR: The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma, in DeVita V, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, pp 329-346
30. Alexander HR, Fraker DL, Bartlett DL: Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 12:416-428, 1996
31. Shaw BW, Martin DJ, Marquez JM, et al: Venous bypass in clinical liver transplantation. Ann Surg 200:524-533, 1984
32. Hoekstra HJ, Naujocks T, Schraffordt-Koops H, et al: Continuous leaking monitoring during hyperthermic isolated regional perfusion of the lower limb: Techniques and results. Reg Cancer Treat 4:301-304, 1992
33. Barker WC, Andrich MP, Alexander HR, et al: Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 22:1242-1248, 1995
34. Eggermont AMM, Koops HS, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 224:756-765, 1996
35. Fraker DL, Alexander HR, Andrich M, et al: Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1:122-130, 1995
36. Nawroth P, Handley D, Matsueda G, et al: Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 168:637-647, 1988
37. Mulé JJ, Asher A, McIntosh J, et al: Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: Tumor size influences the response to therapy. Cancer Immunol Immunother 26:202-208, 1988
38. Olieman AFT, van Ginkel RJ, Hoekstra HJ, et al: Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 4:64-69, 1997
39. Fraker DL: Isolated hepatic infusion perfusion (IHP) with TNF. Cambridge Symposia 11, Hilton Head, SC, March 10-15, 1996
40. Jaskowiak NT, Alexander HR, Bartlett DL, et al: Secondary cytokine production and endocrine effects after high-dose intravascular TNF. Cambridge Symposia 8, 1996
41. Fraker DL, Alexander HR: Isolated perfusion of the liver, in Lotze M, Rubin J (eds): Regional Therapy of Advanced Cancer. Philadelphia, PA, Lippincott, 1998, (in press)
42. Thom AK, Alexander HR, Andrich MP, et al: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol 13:264-273, 1995
43. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356-362, 1992
44. Hack CE, De Groot ER, Felt-Bersma JF, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710, 1989
45. Hack CE, Hart M, van Schijndel RJMS, et al: Interleukin-8 sepsis: Relation to shock and inflammatory mediators. Infect Immun 60:2835-2842, 1992
46. Endo S, Inada K, Inoue Y, et al: Two types of septic shock classified by the plasma levels of cytokines and endotoxin. Circ Shock 38:264-274, 1992
47. Higuchi T, Kikuchi M, Okazaki M: Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer 73:2259-2267, 1994
48. Martinelli DJ, Wadler S, Bakal CW, et al: Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 74:1706-1712, 1994
49. Ravikumar TS, Pizzorno G, Bodden W, et al: Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 12:2723-2736, 1994
50. Curley SA, Newman RA, Dougherty T, et al: Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: A phase I study. Ann Surg Oncol 1:389-399, 1994
51. Feun LG, Reddy KR, Yrizzarry JM, et al: A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. Am J Clin Oncol 17:405-410, 1994
52. Trinchet JC, Rached AA, Beaugrand M: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261, 1995
53. Dudar TE, Jain RK: Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res 44:605-612, 1984
54. Hahn GM, Strande DP: Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Inst 57:1063-1067, 1976
55. Kitamura K, Kuwano H, Matsuda H, et al: Synergistic effects of intratumor administration of cis-diamminedichloroplatinum(II) combined with local hyperthermia in melanoma bearing mice. J Surg Oncol 51:188-194, 1992
56. Barlogie B, Corry PM, Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-Dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40:1165-1168, 1980
57. Klostergaard J, Leroux E, Siddik ZH, et al: Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 52:5271-5277, 1992
58. Asher A, Mulé JJ, Reichert CM, et al: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963-974, 1987
59. Buell JF, Reed E, Lee KB, et al: Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Ann Surg Oncol 4:141-148, 1997
60. Hachiya T, Okada K, Sakurai A, et al: Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia against heterotransplanted human prostatic carcinoma and its lymph node metastasis in nude mice. Mol Biother 4:34-39, 1992
61. Mavligit GM, Zukiwski AA, Charnsangavej C, et al: Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer 69:557-561, 1992
62. Eggermont AMM, Koops HS, Kroon BBBR, et al: The current status of European TNF isolated limb perfusion (ILP) trials in sarcoma, melanoma and carcinoma. Cambridge Symposia 1:12, 1996 (abstr)
63. Holmberg SB, Hafström L, Lindner P, et al: Hyperthermic liver perfusion with tumor necrosis factor and chemotherapy. Eur J Surg Oncol 20:317, 1994 (abstr)
64. Eggermont AMM, Koops HS, Liénard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-gamma and melphalan for irresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 14:2653-2665, 1996
65. Blackwell TS, Christman JW: Sepsis and cytokines: Current status. Br J Anaesth 77:110-117, 1996